Philip A. Philip

18.1k total citations · 4 hit papers
199 papers, 10.8k citations indexed

About

Philip A. Philip is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Philip A. Philip has authored 199 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Oncology, 70 papers in Cancer Research and 69 papers in Molecular Biology. Recurrent topics in Philip A. Philip's work include Pancreatic and Hepatic Oncology Research (76 papers), Colorectal Cancer Treatments and Studies (40 papers) and Cancer Genomics and Diagnostics (31 papers). Philip A. Philip is often cited by papers focused on Pancreatic and Hepatic Oncology Research (76 papers), Colorectal Cancer Treatments and Studies (40 papers) and Cancer Genomics and Diagnostics (31 papers). Philip A. Philip collaborates with scholars based in United States, Canada and Austria. Philip A. Philip's co-authors include Fazlul H. Sarkar, Shadan Ali, Asfar S. Azmi, Anthony F. Shields, Timothy VandenBoom, Yiwei Li, Dejuan Kong, Zhiwei Wang, Ramzi M. Mohammad and B. F. El-Rayes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Philip A. Philip

197 papers receiving 10.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells

2009 552 citations Yiwei Li, Timothy VandenBoom et al. Cancer Research profile →
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

2010 500 citations Philip A. Philip et al. profile →
Neoadjuvant therapy for pancreatic cancer

2023 199 citations Philip A. Philip et al. profile →
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma

2021 175 citations Davendra Sohal, Syed A. Ahmad et al. profile →

Peers

Countries citing papers authored by Philip A. Philip

Since Specialization

Citations

This map shows the geographic impact of Philip A. Philip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip A. Philip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip A. Philip more than expected).

Fields of papers citing papers by Philip A. Philip

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip A. Philip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip A. Philip. The network helps show where Philip A. Philip may publish in the future.

Co-authorship network of co-authors of Philip A. Philip

This figure shows the co-authorship network connecting the top 25 collaborators of Philip A. Philip. A scholar is included among the top collaborators of Philip A. Philip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip A. Philip. Philip A. Philip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505 2025 ·Cancer ·Sameer H. Patel, (unknown), Davendra Sohal, Katherine A. Guthrie, Lisa A. Kachnic, E. Gabriela Chiorean, Andrew M. Lowy, Flavio G. Rocha, Howard S. Höchster, Philip A. Philip, Syed A. Ahmad	2
2	Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges 2025 ·Signal Transduction and Targeted Therapy ·Khalil Choucair, (unknown), Md. Hafiz Uddin, Misako Nagasaka, Mohammed Najeeb Al Hallak, Philip A. Philip, (unknown), Boris Pasche, Asfar S. Azmi	2
3	RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth 2024 ·Cancer Letters ·(unknown), Amro Aboukameel, Husain Yar Khan, Md. Hafiz Uddin, Hyejeong Jang, Eliza W. Beal, (unknown), Yang Shi, Seongho Kim, Kay‐Uwe Wagner, (unknown), Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Muhammad Wasif Saif, Mohammed Najeeb Al Hallak, Boris Pasche, Asfar S. Azmi	2
4	Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors 2024 ·Journal of Ovarian Research ·(unknown), (unknown), Harshit Singh, (unknown), (unknown), (unknown), (unknown), (unknown), Miriana Hijaz, Radhika Gogoi, Philip A. Philip, Adnan Munkarah, Shailendra Giri, Ramandeep Rattan	8
5	Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers 2023 ·Molecular Cancer Therapeutics ·Husain Yar Khan, Misako Nagasaka, Amro Aboukameel, (unknown), Md. Hafiz Uddin, (unknown), (unknown), Ibrahim Azar, Eliza W. Beal, (unknown), Steve Kim, (unknown), Erkan Baloglu, William Senapedis, Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Mohammed Najeeb Al Hallak, Asfar S. Azmi	5
6	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers 2022 ·Cancer Research Communications ·Husain Yar Khan, Misako Nagasaka, Yiwei Li, Amro Aboukameel, Md. Hafiz Uddin, Rachel Sexton, (unknown), (unknown), Mohammed Najeeb Al Hallak, Steve Kim, (unknown), Yosef Landesman, Hirva Mamdani, Dipesh Uprety, Philip A. Philip, Ramzi M. Mohammad, Anthony F. Shields, Asfar S. Azmi	21
7	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus 2021 ·Molecular Cancer Therapeutics ·(unknown), Md. Hafiz Uddin, Mohammed Najeeb Al Hallak, Amro Aboukameel, Yiwei Li, Steve Kim, (unknown), Gregory Dyson, Erkan Baloglu, William Senapedis, Yosef Landesman, Kay‐Uwe Wagner, Nerissa T. Viola, Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	16
8	Molecular Characterization of Appendiceal Goblet Cell Carcinoid 2020 ·Molecular Cancer Therapeutics ·Hiroyuki Arai, Yasmine Baca, Francesca Battaglin, Natsuko Kawanishi, Jingyuan Wang, Shivani Soni, Wu Zhang, Joshua Millstein, Curtis Johnston, Richard M. Goldberg, Philip A. Philip, Andreas Seeber, Joanne Xiu, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, W. Michael Korn, Heinz‐Josef Lenz	18
9	Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma 2020 ·Journal of Surgical Oncology ·Matthew K. Stein, (unknown), Joanne Xiu, (unknown), Michael G. Martin, (unknown), Paxton V. Dickson, Evan S. Glazer, Danny Yakoub, David Shibata, Axel Grothey, Philip A. Philip, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, W. Michael Korn, Heinz‐Josef Lenz, Jeremiah L. Deneve	18
10	Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth 2020 ·Cancers ·Husain Yar Khan, (unknown), Rachel Sexton, Srikant Viswanadha, (unknown), Amro Aboukameel, Maria Diab, Mandana Kamgar, Mohammed Najeeb Al Hallak, (unknown), Anteneh Tesfaye, Steve Kim, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	28
11	Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma 2020 ·ESMO Open ·Andreas Seeber, (unknown), Florian Kocher, Alberto Puccini, Joanne Xiu, Chadi Nabhan, Andrew Elliott, Richard M. Goldberg, Axel Grothey, Anthony F. Shields, Francesca Battaglin, Wafik S. El‐Deiry, Philip A. Philip, John L. Marshall, Michael J. Hall, W. Michael Korn, Heinz‐Josef Lenz, Dominik Wolf‎, Clemens Feistritzer, Gilbert Spizzo	32
12	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer 2019 ·Clinical Cancer Research ·Ryuma Tokunaga, Joanne Xiu, Curtis Johnston, Richard M. Goldberg, Philip A. Philip, Andreas Seeber, Madiha Naseem, Jae Ho Lo, Hiroyuki Arai, Francesca Battaglin, Alberto Puccini, Martin D. Berger, Shivani Soni, Wu Zhang, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, Hideo Baba, W. Michael Korn, Heinz‐Josef Lenz	62
13	Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma 2019 ·Clinical Cancer Research ·Asfar S. Azmi, Husain Yar Khan, Irfana Muqbil, Amro Aboukameel, Jasper E. Neggers, Dirk Daelemans, Amit Mahipal, Gregory Dyson, Mandana Kamgar, Mohammed Najeeb Al Hallak, Anteneh Tesfaye, Steve Kim, Vinod B. Shidham, Ramzi M. Mohammad, Philip A. Philip	40
14	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors 2019 ·Cancers ·(unknown), Amro Aboukameel, Irfana Muqbil, Steve Kim, (unknown), Philip A. Philip, Ramzi M. Mohammad, Mandana Kamgar, Vinod B. Shidham, William Senapedis, Erkan Baloglu, Jing Li, Gregory Dyson, Yue Xue, Bassel F. El‐Rayes, Asfar S. Azmi	24
15	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers 2018 ·Molecular Cancer Research ·Mohamed E. Salem, Alberto Puccini, Axel Grothey, Derek Raghavan, Richard M. Goldberg, Joanne Xiu, W. Michael Korn, Benjamin A. Weinberg, Jimmy J. Hwang, Anthony F. Shields, John L. Marshall, Philip A. Philip, Heinz‐Josef Lenz	159
16	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma 2016 ·Molecular Cancer Therapeutics ·Amro Aboukameel, Irfana Muqbil, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	74
17	Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. 2015 ·PubMed Central ·Shadan Ali, Raagini Suresh, Sanjeev Banerjee, Bin Bao, Zhihong Xu, Jeremy S. Wilson, Philip A. Philip, Minoti V. Apte, Fazlul H. Sarkar	67
18	Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations 2010 ·Molecular Cancer Therapeutics ·Asfar S. Azmi, Zhiwei Wang, Philip A. Philip, Ramzi M. Mohammad, Fazlul H. Sarkar	76
19	Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells breakdown → 2009 ·Cancer Research ·Yiwei Li, Timothy VandenBoom, Dejuan Kong, Zhiwei Wang, Shadan Ali, Philip A. Philip, Fazlul H. Sarkar	552
20	Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma 2009 ·SHILAP Revista de lepidopterología ·Khaldoun Almhanna, Philip A. Philip	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact